Literature DB >> 18640146

The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation.

Sunil Sirohi1, Shveta V Dighe, Ellen A Walker, Byron C Yoburn.   

Abstract

This study determined if fentanyl analgesic efficacy predicts the magnitude of tolerance and mu-opioid receptor regulation. To estimate efficacy, mice were injected i.p. with saline or clocinnamox (CCAM), an irreversible mu-opioid receptor antagonist, (0.32-25.6 mg/kg) and 24 h later fentanyl cumulative dose-response studies were conducted. CCAM dose dependently shifted the fentanyl dose-response function to the right. The apparent efficacy (tau) of fentanyl, based on the operational model of agonism, was estimated as 58, indicating that fentanyl is a high analgesic efficacy agonist. Next, mice were infused with fentanyl (1, 2 or 4 mg/kg/day) for 7 days. Controls were implanted with placebo pellets. At the end of 7 days, morphine cumulative dose-response studies or mu-opioid receptor saturation binding studies were conducted. Fentanyl infusions dose dependently decreased morphine potency with the highest fentanyl dose reducing morphine potency by approximately 6 fold. Chronic infusion with fentanyl (4 mg/kg/day) significantly reduced mu-opioid receptor density by 28% without altering affinity, whereas lower infusion doses had no effect. Taken together, the present results strengthen the proposal that opioid analgesic efficacy predicts mu-opioid receptor regulation and the magnitude of tolerance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640146      PMCID: PMC2597555          DOI: 10.1016/j.pbb.2008.06.019

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  41 in total

1.  Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation.

Authors:  Mary J Clark; Cheryse A Furman; Timra D Gilson; John R Traynor
Journal:  J Pharmacol Exp Ther       Date:  2006-01-25       Impact factor: 4.030

Review 2.  GPCR functional selectivity has therapeutic impact.

Authors:  Richard B Mailman
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

Review 3.  Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

Review 4.  Drug efficacy at G protein-coupled receptors.

Authors:  Terry Kenakin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

5.  Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo.

Authors:  Minesh B Patel; Chintan N Patel; Vikram Rajashekara; Byron C Yoburn
Journal:  Mol Pharmacol       Date:  2002-12       Impact factor: 4.436

6.  Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.

Authors:  Andrew C Barrett; Eric S Smith; Mitchell J Picker
Journal:  J Pharmacol Exp Ther       Date:  2003-03-20       Impact factor: 4.030

Review 7.  The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence.

Authors:  Lene Martini; Jennifer L Whistler
Journal:  Curr Opin Neurobiol       Date:  2007-12-18       Impact factor: 6.627

8.  Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation.

Authors:  Hui Zheng; Horace H Loh; Ping-Yee Law
Journal:  Mol Pharmacol       Date:  2007-10-18       Impact factor: 4.436

9.  Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.

Authors:  Mohit Pawar; Priyank Kumar; Soujanya Sunkaraneni; Sunil Sirohi; Ellen A Walker; Byron C Yoburn
Journal:  Eur J Pharmacol       Date:  2007-02-08       Impact factor: 4.432

10.  Morphine induces endocytosis of neuronal mu-opioid receptors through the sustained transfer of Galpha subunits to RGSZ2 proteins.

Authors:  María Rodríguez-Muñoz; Elena de la Torre-Madrid; Pilar Sánchez-Blázquez; Javier Garzón
Journal:  Mol Pain       Date:  2007-07-17       Impact factor: 3.395

View more
  16 in total

1.  Synergism between fentanyl and tramadol in tonic inflammatory pain: the orofacial formalin test.

Authors:  Hugo F Miranda; Viviana Noriega; Ramiro J Zepeda; Fernando Sierralta; Juan C Prieto
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 2.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

3.  Pharmacokinetics of sustained-release analgesics in mice.

Authors:  Lon V Kendall; Ryan J Hansen; Kathryn Dorsey; Sooah Kang; Paul J Lunghofer; Daniel L Gustafson
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

4.  Determinants of fentanyl and other potent µ opioid agonist misuse in opioid-dependent individuals.

Authors:  Theodore J Cicero; Matthew S Ellis; Alethea Paradis; Zachary Ortbal
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-10       Impact factor: 2.890

5.  Identification of the First Marine-Derived Opioid Receptor "Balanced" Agonist with a Signaling Profile That Resembles the Endorphins.

Authors:  Tyler A Johnson; Laura Milan-Lobo; Tao Che; Madeline Ferwerda; Eptisam Lambu; Nicole L McIntosh; Fei Li; Li He; Nicholas Lorig-Roach; Phillip Crews; Jennifer L Whistler
Journal:  ACS Chem Neurosci       Date:  2016-11-22       Impact factor: 4.418

6.  Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection.

Authors:  Elaine K Lau; Michelle Trester-Zedlitz; Jonathan C Trinidad; Sarah J Kotowski; Andrew N Krutchinsky; Alma L Burlingame; Mark von Zastrow
Journal:  Sci Signal       Date:  2011-08-09       Impact factor: 8.192

7.  Differences in the characteristics of tolerance to μ-opioid receptor agonists in the colon from wild type and β-arrestin2 knockout mice.

Authors:  Hercules T Maguma; William L Dewey; Hamid I Akbarali
Journal:  Eur J Pharmacol       Date:  2012-04-11       Impact factor: 4.432

Review 8.  Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human.

Authors:  Michael M Morgan; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

9.  Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse.

Authors:  Priyanka A Madia; Shveta V Dighe; Sunil Sirohi; Ellen A Walker; Byron C Yoburn
Journal:  Psychopharmacology (Berl)       Date:  2009-10-09       Impact factor: 4.530

10.  The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.

Authors:  Sunil Sirohi; Shveta V Dighe; Priyanka A Madia; Byron C Yoburn
Journal:  J Pharmacol Exp Ther       Date:  2009-05-12       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.